Financial Performance - Total Q2 Net Product Revenues reached $672 million, a 64% increase year-over-year[17, 24] - Total TTR Net Revenues in Q2 were $544 million, representing a 77% year-over-year growth[17] - Rare Franchise Net Product Revenues in Q2 totaled $128 million, a 24% increase year-over-year[28] - Alnylam increased its 2025 Total Net Product Revenue Guidance to a range of $2650 million to $2800 million[17, 74] - The company's Q2 Non-GAAP Operating Income was $95 million[70] Commercial Highlights - U S ATTR-CM launch contributed approximately $150 million in revenue during Q2[33, 34] - There are approximately 1,400 ATTR-CM patients receiving AMVUTTRA as of June 30, 2025[17, 37, 45] - U S TTR franchise experienced 125% year-over-year growth in Q2[32] - GIVLAARI saw a 30% year-over-year growth, driven by an approximately 18% increase in global patients on therapy[29] - OXLUMO experienced a 15% year-over-year growth, driven by an approximately 16% increase in global patients on therapy[29] Pipeline Development - The TRITON-CM Phase 3 study for nucresiran in ATTR-CM has been initiated, with a targeted launch around 2030[17, 60] - Phase 1 multidose results for mivelsiran in Alzheimer's Disease were announced[17] - A Phase 1 study for ALN-4324 in Type 2 Diabetes was initiated[17]

Financial Performance - Alnylam's combined net product revenues reached $469 million, a 28% year-over-year (YoY) increase compared to Q1 2024[15, 25] - The U S TTR franchise primarily drove this growth, experiencing a 45% YoY increase[15] - The company is on track to meet its 2025 financial guidance, projecting combined net product revenues between $2050 million and $2250 million[15] - Non-GAAP operating income was $75 million, resulting in a 13% non-GAAP operating margin[70] Franchise Performance - The Rare Franchise achieved $109 million in global net product revenues in Q1 2025, representing an 8% YoY growth[28] - GIVLAARI sales increased by 15% YoY, driven by a ~15% increase in global patients on therapy[29] - The TTR Franchise experienced a robust 36% growth, primarily driven by U S performance, reaching $359 million in global net product revenues[30, 31] - U S TTR growth was 45% YoY, driven by demand (+32%), inventory (+6%), and gross-to-net adjustments (+7%)[32] AMVUTTRA Launch and Pipeline - AMVUTTRA captured approximately 70% of new hATTR-PN patient starts in the U S in Q1 2025[32, 35] - Alnylam is optimizing access pathways for AMVUTTRA in ATTR-CM at ~170 priority health systems, covering ~80% of Rx volume[39] - Regulatory approvals for AMVUTTRA have been granted in the U S and Brazil, with a positive CHMP opinion in the European Union[56]